



PATIENT NAME : NEPAL SINGH	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Male DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results Biologi	cal Reference Interval Units

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE			
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	14.5	13.0 - 17.0	g/dL	
RED BLOOD CELL (RBC) COUNT	5.39	4.5 - 5.5	mil/µL	
WHITE BLOOD CELL (WBC) COUNT	5.51	4.0 - 10.0	thou/µL	
PLATELET COUNT	90 Low	150 - 410	thou/µL	
Comments				
PLATELET COUNT REDUCED ON SMEAR, CONFIRMED MANN RBC AND PLATELET INDICES	JALLY			
HEMATOCRIT (PCV)	45.1	40 - 50	%	
MEAN CORPUSCULAR VOLUME (MCV)	83.6	83 - 101	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.9 Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	32.2	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW)	16.1 High	11.6 - 14.0	%	
MENTZER INDEX	15.5			
MEAN PLATELET VOLUME (MPV)	15.1 High	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	63	40 - 80	%	
LYMPHOCYTES	24	20 - 40	%	
MONOCYTES	8	2 - 10	%	
EOSINOPHILS	5	1 - 6	%	
BASOPHILS	0	0 - 2	%	
ABSOLUTE NEUTROPHIL COUNT	3.47	2.0 - 7.0	thou/µL	
ABSOLUTE LYMPHOCYTE COUNT	1.32	1 - 3	thou/µL	
ABSOLUTE MONOCYTE COUNT	0.44	0.20 - 1.00	thou/µL	

Chandni Garg

Coracalit

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Dr.Pranjali Vasisht

LAB HEAD

Page 1 Of 21

View Report

View Details

٥í



Ď,





PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 :57 Years ACCESSION NO : 0080WL007441 AGE/SEX Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NEPAM25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHI ABHA NO REPORTED :23/12/2023 13:36:21 : NEW DELHI 110030 8800465156 Test Report Status Results **Biological Reference Interval** Units <u>Final</u> 0.28 thou/µL ABSOLUTE EOSINOPHIL COUNT 0.02 - 0.50 0.00 Low thou/µL ABSOLUTE BASOPHIL COUNT 0.02 - 0.10 NEUTROPHIL LYMPHOCYTE RATIO (NLR) 2.6

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD





Page 2 Of 21

View Details








PATIENT NAME : NEPAL SINGH	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007441	AGE/SEX : 57 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : NEPAM25086680	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:38:33
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 13:36:21
8800465156		
	1	

Test Report	Status	<u>Final</u>
--------------------	--------	--------------

Results

Biological Reference Interval Units

			,		
HAEMATOLOGY					
MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE					
ERYTHROCYTE SEDIMENTATION RATE (ESI BLOOD	ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD				
E.S.R	03	0 - 14	mm at 1 hr		
METHOD : MODIFIED WESTERGREN					
GLYCOSYLATED HEMOGLOBIN(HBA1C), ED BLOOD	TA WHOLE				
HBA1C	5.8 High	Non-diabetic Adult < 5.7	%		
		Pre-diabetes 5.7 - 6.4			
		Diabetes diagnosis: > or =	6.5		
		Therapeutic goals: < 7.0			
Action suggested : > 8.0 (ADA Guideline 2021)					
ESTIMATED AVERAGE GLUCOSE(EAG)	119.8 High	< 116.0	mg/dL		



Diaraht

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD



View Details



Page 3 Of 21







PATIENT NAME : NEPAL SINGH	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680	AGE/SEX : 57 Years Male DRAWN :
DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status Final	Results Biologica	Reference Interval Units

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Deraraht

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD





View Report

Page 4 Of 21

View Details



PERFORMED AT: Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 **DR.CHANDNI GARG** CONSULTANT PATHOLOGIST





PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NEPAM25086680 DRAWN ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHI ABHA NO REPORTED :23/12/2023 13:36:21 : NEW DELHI 110030 8800465156

Test Report Status Final

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE O METHOD : SLIDE AGGLUTINATION TYPE RH TYPE POSITIVE

METHOD : SLIDE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Deraraht

Dr.Pranjali Vasisht LAB HEAD Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 5 Of 21

View Details








PATIENT NAME : NEPAL SINGH	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Male DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

BIOCHEMISTRY				
MEDI WHEEL FULL BODY HEALTH CHEC	K UP ABOVE 40 MALE			
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	97	74 - 106	mg/dL	



mg/dL

Diaraht

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 6 Of 21

1







PATIENT NAME : NEPAL SINGH	REF. DOCTO	R: SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Male DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units

	GLUCOSE, POST-PRANDIAL, PLASMA		
160			
128- 96-	119 •		
64 -		75 🖕	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
0	24-SEP-2022 14:49	23-DEC-2023 13:24	
NormalRange	Date>	 A. S. Martinez, and M. Martinez, Science Strends, 199 	
ID PROFILE WITH CALCU	LATED LDL		
DLESTEROL, TOTAL	169	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
THOD : CHOLESTEROL OXIDASE, EST	ERASE, PEROXIDASE	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
THOD : ENZYMATIC ASSAY	50	< 40 Low >/=60 High	mg/dL
ETHOD : DIRECT MEASURE - PEG	97	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL

Coracalit

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD ne extra Transference

View Details

٥í



Page 7 Of 21




ō,





PATIENT NAME : NEPAL SINGH		REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 001 PATIENT ID : NEF CLIENT PATIENT ID: ABHA NO :	BOWL007441 AGE/SEX :57 Years Male PAM25086680 DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE		
MON HDL CHOLESTEROL	50	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
VERY LOW DENSITY LIPOPROTEIN	22.0	Desirable value : mg/dL 10 - 35
METHOD : CALCULATED PARAMETER		
CHOL/HDL RATIO	3.4	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
	1.9	0.5 2.0 Desirable / ow Rick
LDL/HDL RATIO	1.9	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

METHOD : CALCULATED PARAMETER



Drawlit

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD



View Details




Ŷ.


View Report





PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NEPAM25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHI ABHA NO REPORTED :23/12/2023 13:36:21 : NEW DELHI 110030 8800465156 **Test Report Status** Results Biological Reference Interval Units <u>Final</u>





Interpretation(s)

Diaraht

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST Page 9 Of 21

View Report

View Details







PATIENT NAME : NEPAL SINGH	REF. DOCTOR :	SELF
	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Male DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. **Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India**

Risk Category		
Extreme risk group	A.CAD with > 1 feature of high risk group	
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease	
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemi	a
High Risk	1. Three major ASCVD risk factors. 2. Dia	betes with 1 major risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL >1	90 mg/dl 5. Extreme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipopr	otein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors	
Low Risk	0-1 major ASCVD risk factors	
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ictors
1. Age $>$ or $=$ 45 year	s in males and $>$ or $= 55$ years in females	3. Current Cigarette smoking or tobacco use
2. Family history of p	remature ASCVD	4. High blood pressure
5. Low HDL		

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	1.04	UPTO 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE) BILIRUBIN, DIRECT	0.24	0.00 - 0.30	mg/dL
METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT	0.80 High	0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	6.8	6.6 - 8.7	g/dL
METHOD : BIURET ALBUMIN	4.6	3.97 - 4.94	g/dL

METHOD : BROMOCRESOL GREEN

Coracalit

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT :

GARG

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Page 10 Of 21

View Report

View Details







PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : NEPAM25086680 ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHI ABHA NO REPORTED :23/12/2023 13:36:21 : NEW DELHI 110030 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u> GLOBULIN 2.2 2.0 - 4.0 g/dL Neonates -Pre Mature: 0.29 - 1.04 METHOD : CALCULATED PARAMETER 2.1 High 1.0 - 2.0 RATIO ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER 0 - 40 ASPARTATE AMINOTRANSFERASE 25 U/L (AST/SGOT) U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 27 0 - 41 METHOD : UV WITHOUT PYRIDOXAL-5 PHOSPHATE ALKALINE PHOSPHATASE 109 40 - 129 U/L METHOD : PNPP - AMP BUFFER GAMMA GLUTAMYL TRANSFERASE (GGT) 12 8 - 61 U/L METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE LACTATE DEHYDROGENASE 155 135 - 225 U/L METHOD : LACTATE -PYRUVATE **BLOOD UREA NITROGEN (BUN), SERUM** 6 - 20 **BLOOD UREA NITROGEN** 8 mg/dL METHOD : UREASE - UV

Deraraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report


Page 11 Of 21







PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NEPAM25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHI ABHA NO REPORTED :23/12/2023 13:36:21 : NEW DELHI 110030 8800465156 Biological Reference Interval **Test Report Status Final** Results Units



Deraraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



mg/dL



View Report

View Details



Page 12 Of 21





PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NEPAM25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHÍ REPORTED :23/12/2023 13:36:21 ABHA NO : NEW DELHI 110030 8800465156 Biological Reference Interval **Test Report Status** <u>Final</u> Results Units

<u>_</u> 2,	CREATININE]
2.2			
<u>^</u> 1.76 -			
1.32 -			
0.88 -	0.85	0.84	
-Tpg@u 0.44 -		0.04	
o	and a second		
Biological I	24-SEP-2022 11:49 Reference Interval: 0.70 - 1.20 mg/dl	23-DEC-2023 10:00 Date>	
BUN/CREAT RAT	10		
BUN/CREAT RAT		5.00 - 15.00	
URIC ACID, SER	JM		
URIC ACID METHOD : URICASE, C	OLORIMETRIC 5.8	3.4 - 7.0	mg/dL
TOTAL PROTEIN	SERUM		
TOTAL PROTEIN METHOD : BIURET	6.8	6.6 - 8.7	g/dL
ALBUMIN, SERU	м		
ALBUMIN METHOD : BROMOCRE	4.6 SOL GREEN	3.97 - 4.94	g/dL

GLOBULIN

Diaraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Report







PATIENT NAME : NEPAL SINGH		REF. DOCTOR : S	SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO	: 0080WL007441	AGE/SEX	:57 Years	Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID :	NEPAM25086680	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT	ID:	RECEIVED	: 23/12/2023	8 08:38:33
NEW DELHI 110030	ABHA NO	:	REPORTED	:23/12/2023	3 13:36:21
8800465156					
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval	Units
GLOBULIN	2.2	2.0 - 4.0		g/	dL
		Neonates			
		Pre Mature 0.29 - 1.0			
METHOD : CALCULATED PARAMETER		0.25 110			
ELECTROLYTES (NA/K/CL), SERUM					

ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	143	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.02	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	107	98 - 107	mmol/L
METHOD : ISE INDIRECT			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Drawlit

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 14 Of 21







PATIENT NAME : NEPAL SINGH	REF. DOCTOR :	SELF
	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680	AGE/SEX : 57 Years Male DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Interpretation(s) GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

b>NOTE:
 b>NOTE:
 b>NOTE:
 b>NOTE:
 choose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.
 High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis. Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert

syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease,

Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)
 Lower than normal level may be due to:
 Myasthenia Gravis, Muscuophy
 URIC ACID, SERUM-
Couses of Increased levels:</br>
 DM, Metabolic syndrome
 Causes of decreased levels:
 Lower that how an adverted to the text of measuring the text of measuring in the plagme is made up of allowing and playling.

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Deraraht

Dr.Pranjali Vasisht LAB HEAD

Chandni garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 15 Of 21

View Details







PATIENT NAME : NEPAL SINGH	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WL007441	AGE/SEX : 57 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : NEPAM25086680	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 08:38:33
NEW DELHI 110030	ABHA NO :	REPORTED :23/12/2023 13:36:21
8800465156		

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Results

Biological Reference Interval Units

	CLINICAL PATH - URINALYSI	5	}
MEDI WHEEL FULL BODY HEALTH C	HECK UP ABOVE 40 MALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION, URINE			
PH	7.0	4.7 - 7.5	
METHOD : REFLECTANCE SPECTROPHOTOMETRY- D	OUBLE INDICATOR METHOD		
SPECIFIC GRAVITY	1.005	1.003 - 1.035	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (P	KA CHANGE OF PRETREATED POLY ELECTROLYTES)		
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (P	,		
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY(G	LUCOSE OXIDAE/PEROXIDASE METHOD)		
KETONES	NOT DETECTED	NOT DETECTED	
METHOD · REFLECTANCE SPECTROPHOTOMETRY (S	ODIUM NITROPRUSSIDE REACTION)		

METHOD : REFLECTANCE SPECTROPHOTOMETRY(GLUCOSE OXIDAE	/PEROXIDASE METHOD)	
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (SODIUM NITROP	RUSSIDE REACTION)	
BLOOD	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PEROXIDASE ME	HOD)	
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION		
METHOD . REFLECTANCE SPECTROPHOTOMETRI (DIAZO REACTION)	
UROBILINOGEN	NORMAL	NORMAL
	NORMAL	NORMAL
UROBILINOGEN	NORMAL	NORMAL NOT DETECTED
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY - EHRLICH REACT	NORMAL NOT DETECTED	
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY - EHRLICH REACT. NITRITE	NORMAL NOT DETECTED	

MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			

Drawlit

Dr.Pranjali Vasisht LAB HEAD Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST View Details

Ē.



Page 16 Of 21

View Details







PATIENT NAME : NEPAL SINGH	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080WL007441 PATIENT ID : NEPAM25086680 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :57 Years Male DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CASTS	NOT DETECTED	
CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION		
BACTERIA	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
YEAST	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary		
	tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either		
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by		
	genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or		
	bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,		
	interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal		
	diseases		
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous		
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl		
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of		
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice		
Uric acid	arthritis		

Coracalit

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 17 Of 21

View Details







PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NEPAM25086680 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHÍ REPORTED :23/12/2023 13:36:21 ABHA NO : NEW DELHI 110030 8800465156 **Test Report Status** Biological Reference Interval <u>Final</u> Results Units

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Diaraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 18 Of 21







PATIENT NAME : NEPAL SINGH REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WL007441 AGE/SEX :57 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : NEPAM25086680 : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 DELHI ABHA NO REPORTED :23/12/2023 13:36:21 : NEW DELHI 110030 8800465156

Test Report Status Final

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR

SAMPLE NOT RECEIVED



PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Page 19 Of 21





View Report







PATIENT NAME : NEPAL SINGH	REF. DOCTOR : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : NEPAM25086680 CLIENT PATIENT ID:	AGE/SEX :57 Years Male DRAWN : RECEIVED :23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21
Test Report Status Final	Results Biological	Reference Interval Units

SPECIALISED	CHEMISTRY -	HORMONE
OFECIALIOLD	CHERITOLIKI	HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

<u>Final</u>

THYROID PANEL, SERUM			
ТЗ	99.74	80.00 - 200.00	ng/dL
METHOD : COMPETITIVE (ECLIA)	6.00		<i>,</i>
T4	6.92	5.10 - 14.10	µg/dL
METHOD : COMPETITIVE (ECLIA)			
TSH (ULTRASENSITIVE)	4.350 High	0.270 - 4.200	µIU/mL
METHOD : SANDWICH (ECLIA)			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3 Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Deraraht

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD



View Details



View Report

Test Report Status



REF. DOCTOR : SELF



Male

PATIENT NAME : NEPAL SINGH

CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156

Final

ACCESSION NO : 0080WL007441 AGE/SEX PATIENT ID : NEPAM25086680 DRAWN CLIENT PATIENT ID: RECEIVED : 23/12/2023 08:38:33 REPORTED :23/12/2023 13:36:21 ABHA NO :

> Biological Reference Interval Units

:57 Years

:

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

Results

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form. 2. All tests are performed and reported as per the clinical safety & technical integrity. turnaround time stated in the AGILUS Directory of Services. 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any determine final diagnosis. other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards,

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes. 9 In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Deraraht

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 21 Of 21



